default author photo

Mutsa F. Bwakura-Dangarembizi

University of Zimbabwe - Clinical Trials Research Centre

SCHOLARLY PAPERS

3

DOWNLOADS

203

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): a randomised, open-label, non-inferiority, 96-week trialevaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen (CAB/RPV) compared to daily oral therapy (DTG based TDF or TAF with 3TC or FTC backbone) in virologically suppressed adolescents living with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa

Number of pages: 34 Posted: 30 Oct 2025
affiliation not provided to SSRN, affiliation not provided to SSRN, Joint Clinical Research Centre, Moi University, affiliation not provided to SSRN, Enhancing Care Foundation, University College London - MRC Clinical Trials Unit, Joint Clinical Research Centre, University of Zimbabwe - Clinical Trials Research Centre, Moi University, University of KwaZulu-Natal, Fondazione Penta ETS, affiliation not provided to SSRN, London School of Hygiene & Tropical Medicine - Department of Global Health and Development, Baylor University - Children's Foundation Uganda, Joint Clinical Research Centre, Radboud University Nijmegen - Radboud University Medical Center, Radboud University Nijmegen - Radboud University Medical Center, University of York, University College London - Infection, Immunity and Inflammation Research & Teaching Department, University College London - MRC Clinical Trials Unit, Baylor University - Children's Foundation Uganda, affiliation not provided to SSRN, University College London - MRC Clinical Trials Unit, affiliation not provided to SSRN, University College London - MRC Clinical Trials Unit, Baylor University - Children's Foundation Uganda and University College London - MRC Clinical Trials Unit
Downloads 76 (830,555)

Abstract:

Loading...

HIV, adolescents, cabotegravir and rilpivirine, antiretroviral therapy, injectable, clinical trial

2.

Short-Cycle Therapy (Weekends-Off) on Dolutegravir-Based Antiretroviral Therapy in Adolescents Living with HIV (BREATHER Plus): A Randomised, Open-Label, 96-Week Non-Inferiority Trial

Number of pages: 29 Posted: 10 Sep 2025
Baylor University - Children's Foundation Uganda, University College London - MRC Clinical Trials Unit, University of Zimbabwe - Clinical Trials Research Centre, Joint Clinical Research Centre, Moi University, University of KwaZulu-Natal, University College London - MRC Clinical Trials Unit, Fondazione Penta ETS, Baylor University - Children's Foundation Uganda, University of Zimbabwe, Joint Clinical Research Centre, Moi University, Enhancing Care Foundation, London School of Hygiene & Tropical Medicine - Department of Global Health and Development, Joint Clinical Research Centre, Baylor University - Children's Foundation Uganda, University of York, Radboud University Nijmegen - Radboud University Medical Center, University of Padua - Department of Women’s and Children’s Health, Baylor University - Children's Foundation Uganda, University of Zimbabwe, Moi University, Enhancing Care Foundation, Fondazione Penta ETS, University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit, University College London - Infection, Immunity and Inflammation Research & Teaching Department, University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit and University College London - MRC Clinical Trials Unit
Downloads 73 (852,604)

Abstract:

Loading...

HIV, adolescents, dolutegravir, short cycle therapy, young people, randomised controlled trial

3.

Neuropsychiatric Manifestations and Sleep Disturbances in Children and Adolescents Randomised to Dolutegravir-Based Antiretroviral Therapy vs Standard-of-Care in the Odyssey Trial

Number of pages: 26 Posted: 28 Mar 2023
University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit, Baylor University - Children's Foundation Uganda, University of Zimbabwe - Clinical Trials Research Centre, Joint Clinical Research Centre, Chris Hani Baragwanath Academic Hospital, Makerere University - Johns Hopkins University Research Collaboration, University of the Witwatersrand - Perinatal HIV Research Unit, Khon Kaen University - Khon Kaen Hospital, University of KwaZulu-Natal - Department of Paediatrics and Children Health, Chulalongkorn University - Center of Excellence in Pediatric Infectious Diseases and Vaccines, University of Hamburg - University Medical Center Hamburg-Eppendorf, Institut de Recerca Sant Joan de Deu - Infectious Diseases Department, Khon Kaen University - Khon Kaen Hospital, Baylor University - Children's Foundation Uganda, Mahasarakam Hospital, NSERM/ANRS SC10-US19, Essais Thérapeutiques et Maladies Infectieuses, Joint Clinical Research Centre, Mbarara, University of Zimbabwe - Clinical Trials Research Centre, University College London - Infection, Immunity and Inflammation Research & Teaching Department, Department of Paediatrics, University of Zimbabwe, Joint Clinical Research Centre, Stellenbosch University - Children’s Infectious Diseases Clinical Research Unit (KID-CRU), London School of Hygiene & Tropical Medicine - Department of Clinical Research, University of Padua - Department of Women’s and Children’s Health, Instituto de Investigación 12 de Octubre (imas12) - Pediatric Infectious Diseases Unit, University of the Witwatersrand - Perinatal HIV Research Unit, University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit and Independent
Downloads 54 (1,020,567)

Abstract:

Loading...

Children, adolescents, HIV, dolutegravir, neuropsychiatric, adverse events, mood problems, sleep problems, randomised controlled trial